ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailPositive ArrowIcon Print

Drugmaker Otsuka touches 2017 low as new hits prove elusive

Loss of patent on mainstay antipsychotic has left gaping hole in profit

TOKYO -- Investors are harboring doubts about Japanese drugmaker Otsuka Holdings' growth strategy as new products fail to compensate for declining sales of a former blockbuster.

The company's Tokyo-listed shares fell as much as 4% or so to a year-to-date low of 4,646 yen Tuesday afternoon, with the sell-off quickening after the release of January-June earnings that showed a double-digit net profit decline.

Sponsored Content

About Sponsored Content This content was commissioned by Nikkei's Global Business Bureau.

Discover the all new Nikkei Asia app

  • Take your reading anywhere with offline reading functions
  • Never miss a story with breaking news alerts
  • Customize your reading experience

Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.

Celebrate our next chapter
Free access for everyone - Sep. 30

Find out more